Our Pricing

Understanding Your Wegovy Maintenance Dose: A UK Clinical Guide

Published on: June 03, 2026

Reaching your wegovy maintenance dose uk protocol is a critical milestone in prescription weight loss treatment. At Cured Pharmacy, our UK-registered clinical team supports patients through the complete dose escalation journey to the 2.4mg maintenance dose, ensuring safe, effective long-term weight management with semaglutide.

What Is the Wegovy Maintenance Dose?

The Wegovy maintenance dose is 2.4mg administered once weekly via subcutaneous injection. This represents the maximum therapeutic dose licensed by the MHRA for chronic weight management in adults with obesity or overweight with weight-related comorbidities [1]. Unlike initial titration doses, the maintenance dose is designed for long-term continuation to sustain weight loss and prevent weight regain.

Clinical trials demonstrate that patients who reach and maintain the 2.4mg dose achieve significantly greater weight reduction compared to lower doses. In the STEP 1 trial, participants on the 2.4mg maintenance dose lost an average of 14.9% of their initial body weight over 68 weeks, compared to 2.4% with placebo [1]. This maintenance phase is where the most substantial and sustained weight loss occurs.

Patients typically reach the maintenance dose after completing a 16-week dose escalation schedule, though individual timelines may vary based on tolerability and prescriber assessment. Once established on 2.4mg weekly, most patients continue this dose indefinitely as part of a comprehensive weight management programme including dietary modification and increased physical activity.

Wegovy Dose Escalation Schedule to Maintenance

The journey to your wegovy maintenance dose uk follows a structured escalation protocol designed to minimise gastrointestinal side effects whilst optimising efficacy. The MHRA-approved titration schedule spans 16 weeks, with dose increases every four weeks [2].

Week 1-4: 0.25mg once weekly. This introductory dose allows your body to adjust to semaglutide's effects on gastric emptying and appetite regulation. Week 5-8: 0.5mg once weekly, doubling the initial dose as tolerance develops. Week 9-12: 1.0mg once weekly, entering the lower therapeutic range. Week 13-16: 1.7mg once weekly, the penultimate step before maintenance. Week 17 onwards: 2.4mg once weekly, the full maintenance dose [2].

This gradual escalation is critical for treatment adherence. Research shows that patients who follow the prescribed titration schedule experience fewer treatment discontinuations due to nausea, vomiting, and diarrhoea compared to those attempting faster dose increases. Your UK prescriber may adjust this timeline based on individual tolerance, occasionally extending time at lower doses if gastrointestinal symptoms are pronounced.

Managing Side Effects During Dose Escalation

Gastrointestinal side effects peak during the first few weeks after each dose increase, typically subsiding as your body adapts. Nausea affects approximately 44% of patients during escalation but usually diminishes within days of each new dose [1]. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can significantly reduce symptom severity. If side effects remain intolerable at any dose level, your prescriber may recommend staying at the current dose for an additional month before attempting further escalation.

How Long Should You Stay on Wegovy Maintenance Dose?

Wegovy is licensed for long-term chronic weight management, meaning the maintenance dose is designed for indefinite continuation rather than short-term use. Clinical evidence from the STEP trials demonstrates that weight loss plateaus around 60-68 weeks on the 2.4mg maintenance dose, after which weight stabilises at the reduced level [1][3].

Crucially, discontinuation of Wegovy typically results in weight regain. The STEP 4 trial specifically examined this phenomenon: participants who stopped semaglutide after 20 weeks on maintenance dose regained approximately two-thirds of their lost weight over the subsequent 48 weeks, whilst those who continued treatment maintained their weight loss [3]. This underscores that obesity is a chronic condition requiring ongoing pharmacological management.

Your UK prescriber will conduct regular reviews—typically every three to six months—to assess treatment response, monitor for adverse effects, and evaluate whether continuation remains clinically appropriate. Factors influencing long-term treatment decisions include sustained weight loss of at least 5% from baseline, improvement in weight-related comorbidities such as type 2 diabetes or hypertension, tolerability of the medication, and patient preference. At Cured Pharmacy, priced from £79.00, Wegovy maintenance treatment remains accessible for long-term use with transparent upfront pricing and ongoing prescriber support.

When Might Maintenance Dose Be Adjusted?

Whilst 2.4mg weekly is the standard maintenance dose, some patients may require dose modification. If intolerable side effects persist despite dietary adjustments and symptom management strategies, your prescriber may reduce the dose to 1.7mg as a long-term maintenance alternative, though efficacy may be somewhat reduced. Conversely, if you miss several consecutive doses, your prescriber will likely restart the escalation schedule from a lower dose to minimise gastrointestinal distress upon resumption.

Wegovy Maintenance Dose vs Other Weight Loss Treatments

Understanding how Wegovy's maintenance dosing compares to alternative weight loss medications helps inform treatment selection. Semaglutide (Wegovy's active ingredient) is a GLP-1 receptor agonist, but newer dual-action treatments and daily injection alternatives offer different maintenance protocols.

Saxenda (liraglutide) requires daily injections at a maintenance dose of 3.0mg, compared to Wegovy's once-weekly 2.4mg administration. Clinical head-to-head data shows semaglutide produces greater weight loss than liraglutide—approximately 14.9% versus 7.8% body weight reduction respectively [1][4]. The weekly dosing schedule of Wegovy often proves more convenient for long-term adherence compared to daily injections.

Tirzepatide-based treatments represent the newest class of weight loss medications, with dual GIP/GLP-1 receptor agonist activity. Maintenance doses range from 10mg to 15mg weekly, with clinical trials showing average weight reductions of up to 22.5% at the highest maintenance dose [5]. However, tirzepatide is not yet widely available for weight management in the UK outside of specialist services, and pricing typically exceeds that of semaglutide-based options.

Maximising Results on Wegovy Maintenance Dose

Achieving optimal outcomes on the wegovy maintenance dose uk protocol requires integration with lifestyle modifications. Semaglutide enhances weight loss efforts by reducing appetite and increasing satiety, but it is not a standalone solution. NICE guidelines emphasise that GLP-1 receptor agonists should be prescribed alongside a reduced-calorie diet and increased physical activity programme [6].

Nutritional strategies that complement Wegovy include prioritising protein intake to preserve lean muscle mass during weight loss, aiming for 1.2-1.6g per kilogram of body weight daily. Adequate protein intake also enhances satiety, working synergistically with semaglutide's appetite-suppressing effects. Focus on whole foods rich in fibre—vegetables, fruits, whole grains, and legumes—which slow gastric emptying and further reduce hunger between meals.

Physical activity accelerates weight loss and improves metabolic health markers beyond what medication alone achieves. Current UK guidelines recommend at least 150 minutes of moderate-intensity aerobic activity weekly, plus resistance training twice weekly to maintain muscle mass. Patients combining Wegovy maintenance dose with structured exercise programmes demonstrate superior improvements in cardiovascular fitness, insulin sensitivity, and body composition compared to medication alone [6].

Monitoring Progress on Maintenance Dose

Regular monitoring ensures your maintenance dose continues delivering clinical benefit. Beyond tracking weight, monitor waist circumference, blood pressure, fasting glucose, and HbA1c if you have prediabetes or type 2 diabetes. These markers often improve substantially on Wegovy maintenance therapy. Your UK prescriber will assess these parameters during follow-up consultations to determine whether treatment continuation remains appropriate and whether dose adjustments might optimise outcomes.

Getting Started with Wegovy at Cured Pharmacy

Accessing Wegovy maintenance dose treatment through Cured Pharmacy combines clinical expertise with transparent, competitive pricing. As a UK-registered online pharmacy (GPhC Registration Number 9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073), we provide genuine UK-licensed Wegovy with full regulatory compliance and clinical oversight.

The process begins with a free online consultation taking under three minutes, completed entirely through our secure platform. Our UK-registered prescribers review your medical history, current medications, weight management goals, and any contraindications to semaglutide therapy. All prescription medications require clinical assessment by a UK prescriber—there are no exceptions to this regulatory requirement.

Following prescriber approval, Wegovy is dispensed from our UK pharmacy and delivered in 100% discreet packaging directly to your address. Pricing starts from £79.00 with transparent upfront costs displayed before consultation, eliminating surprise fees. Ongoing prescription renewals follow the same streamlined process, with regular prescriber reviews ensuring safe, effective long-term maintenance dose therapy. Our clinical team remains available via phone (+44) 116 4646009 throughout your treatment journey to address questions about dose escalation, side effect management, or optimising results on your wegovy maintenance dose uk protocol.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
4. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. Retrieved from https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.